$THC

Romo Tammy sold $2.0M of THC

Romo Tammy sold 7,422 shares of TENET HEALTHCARE CORP (THC) at an average of $263.03 ($260.83–$264.15, $1.95M total) across 2 trades over 2026-08-06 to 2026-08-07.

Original reporting
SEC EDGAR · Romo Tammy
Published Aug 11, 2026, 12:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 11, 2026, 12:04 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$THC
Neutral
medium confidence
Mentioned
$THC
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$THCNeutralLow
01

Why it matters

The disclosure updates the record of insider activity and can influence short-term sentiment, but it does not provide new information about Tenet’s operations, financial results, or guidance.

02

Market read

Traders may monitor insider selling as a sentiment input, but the filing alone is not a fundamental catalyst.

03

What to watch

Insider sales often reflect diversification, taxes, or pre-scheduled liquidity needs; the article provides no reason for the sale or any link to company performance.

Relevance 6/10Novelty 3/10Timing: filed 2026-08-10 for trades dated 2026-08-06 to 2026-08-07

Background

The article is an SEC Form 4 insider transaction disclosure for Tenet Healthcare Corp, reported by director Romo Tammy.

Company-level read

Ticker impact

$THCNeutralMedium confidence
Context

Tenet Healthcare director Romo Tammy filed Form 4 showing an open-market sale of 7,422 shares at about $260.83 to $264.15.

Expected impact

Low likelihood of a sustained price move; any reaction is likely limited to short-term sentiment.

Evidence & confidence

The filing is a routine Form 4 open-market sale with no 10b5-1 plan and no accompanying operational or guidance change disclosed in the text.

Market effects

No sector-level implications are provided; this is company-specific insider transaction data.

None indicated.

None indicated.

Counterpoint

Because the sale is not tied to a stated 10b5-1 plan in the text, some traders may overinterpret it as bearish despite being a small, routine insider transaction.

Key entities

  • Tenet Healthcare Corp

    Subject of the Form 4 insider transaction disclosure.

  • Romo Tammy

    Director who sold shares in open-market transactions.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$THCMed

Tenet Healthcare (THC) Refinances Debt On A Fair Value Story That Looks Tightly Priced

Tenet Healthcare (THC) issued $2b in 6.250% senior notes due 2034 to refinance existing debt. Its share price has risen 25.4% in 90 days and 29.7% year-to-date. The company's fair value is estimated at $260, slightly above its current price of $258.62. Management's cost-reduction efforts have lowered contract labor and certain analytics costs, but further margin expansion may be limited.

$THCMed

Can THC's Cash Flow Support Its Expanding Capital-Return Strategy?

Tenet Healthcare (THC) reported a 27.1% year-over-year increase in operating cash flow to $2.2B in H1 2026, raising its adjusted free cash flow guidance to $1.825B-$2.055B. The company spent $1.4B on share buybacks and increased its repurchase authorization by $2B. THC is balancing buybacks with growth investments, expecting $700M-$800M in capital spending. Peers UHS and HCA also reported significant buybacks and capital investments.

$THCMed

Is Tenet Healthcare Corporation (THC) A Solid Play on Expanding Ambulatory Business?

Tenet Healthcare (THC) is focusing on its ambulatory business for growth, with BMO Capital Markets noting favorable long-term trends and margins. USPI, Tenet’s ambulatory platform, reported 9.3% revenue growth in Q2. BMO initiated coverage with a Market Perform rating and $265 price target. Hedge funds increased stakes, while short interest declined. Risks include reimbursement changes and competition.

$THCMedAI 8/10

What Tenet Healthcare (THC)'s $2 Billion Debt Refinance Means For Shareholders

Tenet Healthcare (THC) completed a $2 billion private placement of senior unsecured notes due 2034 at a 6.250% coupon. Proceeds will redeem $1.5 billion of 2027 secured notes and $0.5 billion of 2028 senior notes, altering its capital structure and interest obligations. Analysts project revenues of $24.1 billion and earnings of $1.6 billion by 2029, with some seeing potential upside.

$THCMedAI 8/10

What Tenet Healthcare (THC)'s $2b Debt Refinance Means For Shareholders

Tenet Healthcare (THC) priced a $2.0 billion private placement of 6.250% senior notes due 2034, upsized from $1.5 billion, to refinance existing 2027 and 2028 debt. The refinancing replaces secured and partly secured borrowings with unsecured notes, altering the company's debt structure. Investors focus on execution, pricing, and free cash flow, with high debt and earnings declines noted as risks.